Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

摘要: Androgens exert growth inhibitory effects on estrogen receptor and progesterone receptor-negative breast cancer cell lines that show androgen expression. These laboratory findings may be translated into inexpensive alternative therapies for hormone invasive cancers. Our aim was to systematically evaluate expression by immunohistochemistry in Androgen (clone AR441, Dako) analyzed 189 well-characterized consecutive carcinomas represented with threefold redundancy tissue microarrays. semi-quantitated using a histochemical score-like method score >10 considered positive. Of the cancers, 151 (80%) were positive 38 (20%) negative receptor. The majority (95%) of receptor-positive tumors also tumors, reactivity seen 3 30 (10%) triple-negative cases 5/8 (63%) receptor-negative/progesterone receptor-negative/HER2+ cases. Six eight receptor-negative/androgen showed apocrine differentiation. associated smaller tumor size (P=0.0001), lower Nottingham grade (P=0.002) less frequent necrosis (P=0.0001). (P=0.005) differentiation (P=0.039). In conclusion, most express (which commonly differentiation) subset triple - suggest these together comprises 'molecular apocrine' group described previously. However, should further confirmed larger series negative/progesterone negative/HER2+ tumors. receptor-targeted therapy estrogen/progesterone provide an usual high-dose chemotherapy or without trastuzumab.